Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Intangibles (2016 - 2022)

Abeona Therapeutics has reported Intangibles over the past 11 years, most recently at $2.2 million for Q3 2022.

  • Quarterly results put Intangibles at $2.2 million for Q3 2022, up 52.58% from a year ago — trailing twelve months through Sep 2022 was $2.2 million (up 52.58% YoY), and the annual figure for FY2021 was $1.4 million, down 7.73%.
  • Intangibles for Q3 2022 was $2.2 million at Abeona Therapeutics, roughly flat from $2.2 million in the prior quarter.
  • Over the last five years, Intangibles for ABEO hit a ceiling of $43.0 million in Q4 2018 and a floor of $1.4 million in Q4 2021.
  • Median Intangibles over the past 5 years was $2.6 million (2020), compared with a mean of $11.1 million.
  • Biggest five-year swings in Intangibles: surged 1046.25% in 2019 and later tumbled 93.88% in 2020.
  • Abeona Therapeutics' Intangibles stood at $43.0 million in 2018, then dropped by 1.01% to $42.6 million in 2019, then crashed by 96.48% to $1.5 million in 2020, then fell by 7.73% to $1.4 million in 2021, then skyrocketed by 55.78% to $2.2 million in 2022.
  • The last three reported values for Intangibles were $2.2 million (Q3 2022), $2.2 million (Q2 2022), and $2.2 million (Q1 2022) per Business Quant data.